Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors STING, a small molecule that binds to the stimulator of interferon genes in cancer CellPorter, a cell permeable peptide platform technology derived from human proteins PPL-003, an ophthalmic solution and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.